Recombinant SMAD4 抗体 (full length)
Our Local Distributor
北京 101111
Quick Overview for Recombinant SMAD4 抗体 (full length) (ABIN7869466)
抗原
See all SMAD4 抗体抗体类型
适用
宿主
克隆类型
标记
应用范围
质量等级
克隆位点
-
-
抗原表位
- AA 1-552, full length
-
原理
- Recombinant SMAD4 Antibody (azide and preservative free)
-
纯化方法
- Protein A/G affinity
-
免疫原
- Recombinant human full-length SMAD4 protein (amino acids 1-552) was used as the immunogen for the recombinant SMAD4 antibody.
-
亚型
- IgG
-
-
-
-
应用备注
- Optimal dilution of the recombinant SMAD4 antibody should be determined by the researcher.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 mg/mL
-
缓冲液
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
储存液
- Azide free
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Aliquot the recombinant SMAD4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- SMAD4 (SMAD Family Member 4 (SMAD4))
-
别名
- SMAD4
-
背景
- Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF- family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. The lack of SMAD4 expression is present in approximately 80 % of cases of pancreatic adenocarcinoma, but rarely in endometrial (0 %), colorectal (0 %), ovarian (3 %), lung (0 %), breast (2 %) adenocarcinomas, and malignant melanoma (4 %). SMAD4is an important marker for confirming a diagnosis of pancreatic adenocarcinoma.
-
UniProt
- Q13485
-
途径
- Cell Division Cycle, Chromatin Binding, Autophagy
抗原
-